Stock Ratings / Health Care / ESLA / options

ALGS (26) MGX (41) GNTA (62) ELUT (34) ⌘ Pro Terminal →

Estrella Immunopharma Inc. (ESLA) Options Positioning, Max Pain & Unusual Sweeps

$0.73 -11.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.71

Estrella Immunopharma Inc. (ESLA) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $31.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.71 (-2.23%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ESLA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY ESLA SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.41+4.9% Next Q

Q2 (-2Q)

Grade E$0.43+130.2% Next Q

Q3 (-1Q)

Grade E$0.99-26.3% Next Q

Current

Grade D-$0.73-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ESLA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ESLA currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.58) and Max Pain ($0.77) forces dealer call-delta covering toward $3.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ESLA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ESLA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ESLA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ESLA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ESLA)

✓Walkthrough of ESLA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ESLA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.49%📐 HORIZONTAL RANGE

2026-10-30O $0.72H $0.79L $0.62C $0.73VOL 165.7K

RES: $1.17SUP: $0.17SMA50: $0.58SMA200: $0.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ESLA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ESLA Butterfly Map → + Track ESLA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ESLA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ESLA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ESLA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ESLA)

Health Care Rank #620 of 1016 ⚔️ ALGS vs ESLA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ESLA vs. ALGS, MGX, GNTA, ELUT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Estrella Immunopharma Inc. (ESLA) ranks #620 by composite RQD confidence (41/100, grade D-) and #798 by equity capitalization ($31.7M). Within this direct 5-issuer industry benchmark cohort, ESLA leads on earnings valuation at N/A trailing P/E, while ESLA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with ESLA at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ESLA ACTIVE Estrella Immunopharma Inc.	D-	41/100	—	—	-35.0%	-11.32%	$31.7M	Benchmark Subject
ALGS Aligos Therapeutics Inc.	E	26/100	—	—	-35.0%	-2.71%	$31.4M	/algs-vs-esla →
MGX Metagenomi Therapeutics Inc.	D-	41/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-esla →
GNTA Genenta Science S.p.A.	C	62/100	—	—	—	+2.48%	$29.9M	/gnta-vs-esla →
ELUT Elutia Inc. (Class A)	E	34/100	—	53.7%	-35.0%	-3.13%	$36.0M	/elut-vs-esla →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001844417

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Estrella Immunopharma Inc. (ESLA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.1M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (+88.9% YoY). On the balance sheet, ESLA closed FY2025 with $3.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$13.1M	-$1.8M	-$1.8M	$3.2M	—
FY2024 (FY)	2024-06-30	$0	-$7.3M	-$16.1M	-$16.1M	$3.1M	—
FY2023 (FY)	2023-06-30	$0	-$11.1M	-$1.3M	-$1.3M	—	—

3. ESLA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ESLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Estrella Immunopharma Inc. (NASDAQ: ESLA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.73 (-11.32% 1D, market cap $31.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ESLA ranks #620 in composite RQD confidence.

How does ESLA compare to ALGS and MGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ESLA carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALGS (Aligos Therapeutics Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and MGX (Metagenomi Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, ESLA leads on earnings multiple (N/A) while ESLA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ESLA?

Per ESLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001844417), Estrella Immunopharma Inc. generated $0 in revenue, -$13.1M in net income, and -$1.8M in free cash flow against $3.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ESLA trading relative to its 50-day, 200-day, and 52-week technical levels?

ESLA last traded at $0.73 (-11.32% on volume of 271,206 shares), positioning the stock +25.86% above its 50-day simple moving average ($0.58) and -26.26% below its 200-day simple moving average ($0.99). Across its 52-week range of $0.24 to $3.15, ESLA sits at the 16.8% percentile with a 14-day RSI of 51.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).

ESLA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ESLA's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ESLA.

Direct Sub-Reports: ESLA RQD Cockpit ESLA 12M Forecast ESLA Earnings & Move ESLA Dividends & DRIP ESLA Insiders & 13F ESLA Whale Options ESLA Profit Sankey ESLA News & Why